Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from JJ.

South Africa ‘held to ransom’ by big pharma, overcharged for COVID vaccines

J&J, Pfizer charged South Africa between 15 and 33 percent more for COVID vaccine doses, contracts reveal.

Al Jazeera

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

The Guardian - UK

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

Fortune

Explained | Will generic supply of bedaquiline be accessible?

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

The Hindu

J&J Stock Roars Higher, Retaking Its 200-Day Line As Small Drugs Drive Big Beat

Johnson & Johnson beat quarterly expectations Thursday, helped by its new cancer drug Carvykti, and JNJ stock surged.

Investors Business Daily

MSF calls again on J&J to withdraw or abandon extended patents on lifesaving TB drug as main patent expires in India

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Cheaper TB drugs for millions after global deal on patent rights agreed

Johnson & Johnson allows generic bedaquiline in 44 countries – but concerns remain about ‘stopgap’ solution

The Guardian - UK

Johnson and Johnson shares licence for tuberculosis drug after novelist’s viral campaign

Disease kills millions each year even though it’s curable

The Independent UK

Future Fortune 500 CEOs: 11 up-and-comers that leadership experts see as generational standout bosses

Fortune has identified 11 CEO stars in the making—many of them already in the C-suite, and all potential large-company CEOs.

Fortune

Edinburgh to get huge Harry Styles Aftershow Parties with 'Harryoke' and star's hits

The Love On Tour Aftershow Party is coming to Edinburgh, with the event hosted by the Harry’s House Party, the creators of the original Harry Styles and One Direction club night.

Edinburgh Live

PRS Sonzera 20 Combo review

Reworked, redesigned, reinvigorated, PRS's versatile combo returns – and it's a bona-fide 20-watt powerhouse of tone

Guitar World

J&J wins pause of baby powder trials, must face new suits

Johnson & Johnson must face new lawsuits accusing the company of selling tainted baby powder that caused cancer, a judge ruled, opening the company up to court actions that had been halted for 19 months.

Tribune News Service

Legend Breaks Out After Leaked Documents Show Promise In $9.6 Billion Market

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Surprising Source Of Johnson & Johnson's First-Quarter Beat And Raise

Johnson & Johnson beat first-quarter expectations Tuesday and raised its full-year outlook. But JNJ stock ended the trading day lower.

Tribune News Service

J&J’s first attempt to escape cancer claims with bankruptcy failed. Now it’s trying again

Johnson & Johnson’s first attempt at using bankruptcy to escape claims that its popular baby powder caused cancer was an expensive gamble that drew public scorn and ended in failure.

Investors Business Daily

Johnson & Johnson Pops After Sweetening Its Talc Settlement By Nearly $7 Billion

J&J reached an $8.9 billion settlement in ongoing litigation over its talc-based baby powders, leading JNJ stock to rise Wednesday.

The Guardian - UK

First Thing: Trump attacks hush money case in grievance-filled Mar-a-Lago speech

Former president appeared subdued in New York, only to return to his inflammatory ways in Florida. Plus, the campaigners using using dating apps to boost voter turnout

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

Johnson & Johnson proposes paying $8.9 billion to settle talcum powder lawsuits

Under a proposal, a J&J subsidiary will re-file for bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

The Independent UK

Johnson & Johnson proposes $8.9bn settlement fund for talcum powder cancer lawsuits

The offer will have to be approved by a bankruptcy judge

Chicago Sun-Times

Johnson & Johnson proposes $8.9 billion payout to settle talcum powder lawsuits

A subsidiary of the company will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

The Independent UK

J&J proposes paying $8.9B to settle talcum powder lawsuits

Johnson & Johnson is earmarking nearly $9 billion to cover allegations that its baby power containing talc caused cancer

Investors Business Daily

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.

Investors Business Daily

How J&J's Mostly Defunct Covid Shot Still Managed To Hamper Sales; Danaher Dives

Covid vaccines took a major toll on Johnson & Johnson and Danaher early Tuesday, hitting J&J's fourth-quarter sales and Danaher's guidance.

Tribune News Service

Employers use patient assistance programs to offset their own costs

Anna Sutton was shocked when she received a letter from her husband’s job-based health plan stating that Humira, an expensive drug used to treat her daughter’s juvenile arthritis, was now on a long list of medications considered “nonessential benefits.”

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.